The fast growth of biologics manufacturing is altering the pharmaceutical and biotechnology sectors and creating a need for sophisticated safety measures throughout the manufacturing process. Of these methods, viral inactivation has become an important step in guaranteeing the safety, effectiveness and regulatory compliance of biologic goods. From monoclonal antibodies and recombinant proteins to vaccinations and plasma-derived medicines, manufacturers depend more and more on effective viral clearance techniques to ensure patient health and reduce contamination concerns.
As the complexity of biologics pipelines continues to grow and manufacturing quantities increase, international regulatory bodies are imposing strict standards for virus safety. This has increased the use of viral inactivation technologies such as solvent detergent treatment, low pH inactivation and nanofiltration. These technologies are essential to remove or inactivate viral contamination and maintain the integrity of therapeutic solutions.
The Viral Inactivation Market size was USD 0.72 billion in 2025 and is anticipated to reach USD 2.27 billion by 2035 with a CAGR of 12.30% during the forecast period (2026-2035). The market’s growth is significantly driven by increased investments in biopharmaceutical research, the increasing demand for biologics, and a heightened emphasis on product safety within global healthcare systems.
Top 5 Viral Inactivation Companies Fueling Industry Growth
1. Merck KGaA
A leader in life science solutions for the research and manufacture of biologics, Merck KGaA is establishing itself as a supplier. Our line of viral clearance products – industrial filtration systems, process chemicals and integrated technologies – is intended to help businesses satisfy the most strict regulatory requirements. By investing in research and process optimization, Merck actively enables pharmaceutical firms to enhance production efficiency without compromising product safety.
Why Merck KGaA is a Leader in Viral Safety Innovation
• Total viral filtering and clearing solutions
• Strong emphasis on biologics manufacturing support
• Extensive experience in process development and validation
• Global footprint in pharmaceutical and biotechnology markets
2. Sartorius AG
Sartorius AG is a major contributor to the development of bioprocessing technology for the pharma sector. The firm provides unique technologies that enable viral inactivation, filtration and purification throughout the biologics manufacturing process. Its solutions assist manufacturers to optimize operations while meeting growing regulatory requirements.
With the need for sophisticated therapies on the rise, Sartorius is committed to delivering scalable solutions that enhance process dependability and product quality.
Sartorius Expands State-of-the-Art Bioprocessing Capabilities
• Enhanced filtration and purification processes
• Leading position in upstream and downstream processes
• Commercial manufacture of biologics – scalable solutions
• Emphasis on process efficiency and conformity to regulations
3. Charles River Labs
Charles River Laboratories is a leading provider of critical services that enable drug discovery, development and manufacture. The firm provides viral clearance research and validation services allowing biopharmaceutical producers to test and validate viral inactivation procedures.
With scientific experience and regulatory know-how, Charles River is a trusted partner for enterprises wanting to bring biologic treatments to market safely and efficiently.”
Trustworthy Validation of Viral Clearance by Charles River
• Complete viral safety testing services
• Knowledge of regulatory and compliance needs
• Strong support for biologics development programs
• Improved laboratory capacity for viral risk assessment
4. Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific is one of the world’s major suppliers of scientific solutions and laboratory equipment. The firm offers a wide spectrum of products and services supporting viral inactivation and biologics manufacture. It offers filtration systems, analytical equipment and process development solutions that assist pharmaceutical firms to maintain product quality and safety.
The worldwide presence and technology know-how of the firm continue to make it one of the key players in the viral inactivation industry.
Thermo Fisher Expands Biopharma Manufacturing Capabilities
• Portfolio diversity for process of viral clearance
• Advanced process development and analytical technologies
• Strong client base in pharmaceutical sectors
• Ongoing innovation in biologics manufacturing solutions
5. Lonza Group
The Lonza Group has earned a solid reputation as a worldwide contract development and manufacturing company for the pharmaceutical and biotechnology markets. The company’s manufacturing services are supported by viral inactivation and clearing technologies that enable clients to speed product development while maintaining high quality requirements.
With broad expertise in biologics manufacturing and process optimization, Lonza helps clients meet growing regulatory expectations and market demands.
Lonza Provides Integrated Viral Safety Solutions
• End-to-end biologics manufacturing support
• Enhanced viral inactivation and clearance capabilities
• Significant expertise in contract development and manufacturing
• High focus on quality assurance and regulatory compliance
Market Growth Driven by Rising Demand for Biologics
The global usage of biologic medicines is driving the expansion of the viral inactivation market. Pharmaceutical firms are spending substantially on monoclonal antibodies, recombinant proteins, vaccines and plasma derived medicines to treat a wide variety of disorders. As these medicines get more complex, producers will need to develop strong viral safety precautions throughout the manufacturing process.
The industry’s dedication to product safety without sacrificing therapeutic efficacy is shown by the extensive use of solvent/detergent treatment, low pH inactivation and nanofiltration technology. These techniques have become integral parts of contemporary biopharmaceutical manufacturing and are predicted to continue to be vital in the face of increasing production numbers.
Innovation and Compliance will define the future
As the biopharmaceutical industry continues to change, viral safety will remain a high focus for producers, regulators and health care providers. Merck KGaA, Sartorius AG, Charles River Laboratories , Thermo Fisher Scientific Inc. and Lonza Group are helping to move forward the technology and services required to address the rising worldwide demand for safe biologic treatments.
The market for viral inactivation is expected to expand significantly over the next decade, driven by increased investment in the development of biologics and stringent regulatory control. “The continued collaboration between technology providers, manufacturers and research organizations will be key to strengthening pharmaceutical safety and enabling the development of the next generation of innovative therapies.
